J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials

Commentary
Video

The associate professor at MD Anderson Cancer Center discussed the upcoming trial of NY-ESO-1 TCR/IL-15 NK cell therapy for SS and MRCLS.

“We're very excited to bring forward a new study, it's looking at a novel therapy, it's cord blood-derived T-cell receptor natural killer cells. This is going to be a first-in-human study using this new cell therapy for patients with synovial sarcoma and myxoid/round cell liposarcoma. So, there's been a lot of interest in immunotherapy for these 2 sarcoma subtypes previously, and in particular, targeting cancer testis antigens like NY-ESO. So, this study will really build on some of that science and some of the prior therapies, but particularly novel using a TCR... It’s one of the first studies to really look at this type of treatment, and in particular, in patients with solid tumors.”

MD Anderson and Syena are soon initiating a first-in-human phase 1/1b trial of their T-cell receptor natural killer (TCR NK) cell therapy NY-ESO-1 TCR/IL-15 NK in patients with advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL). The FDA cleared the investigational new drug (IND) application for the therapy in June 2023.

CGTLive spoke with J. Andrew Livingston, associate professor in the department of sarcoma medical oncology and the department of pediatrics patient care at the University of Texas MD Anderson Cancer Center, who will serve as the study’s primary investigator, to learn more about the upcoming trial. He touched on previous research in the field that the study is building upon with the new TCR NK therapy. He also discussed the biggest challenges with treating sarcomas, which lie in the disease’s rarity and heterogeneity.

REFERENCE
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma. News release. MD Anderson. June 20, 2023. https://www.mdanderson.org/newsroom/novel-tcr-nk-cell-therapy-sarcoma-receives-ind-clearance-fda.h00-159619434.html

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.